TABLE 1.
Buffer formulations used in this studya
| Test substance (concn in buffer) | Mode of action | Base buffer | Solvent (%) | Matched control buffer |
|---|---|---|---|---|
| Valinomycin (10 μM) | K+ ionophore | Valinomycin buffer | MeOH (0.1) | Valinomycin buffer + 0.1% MeOH |
| FCCP (10 μM) | Protonophore | PBS/G | MeOH (0.1) | PBS/G + 0.1% MeOH |
| Arsenate (50 μM) | ATP poison | ArBS-K/G | Water | PBS-K/G |
| DCCD (10 μM) | F0F1 ATPase inhibitor | PBS/G | EtOH (0.025) | PBS/G + 0.025% EtOH |
| Sodium orthovanadate (1 mM) | P-type ATPase inhibitor | PBS-K/G | Water | PBS-K/G |
| Phenamil (10 μM) | Sodium channel blocker | PBS/G | MeOH (0.1) | PBS/G + 0.1% MeOH |
| Amiloride (10 μM) | Sodium channel blocker | PBS/G | Water | PBS/G |
| Rifampin (5 μg/ml) | RNA synthesis inhibitor | PBS/G | MeOH (0.1) | PBS/G + 0.1% MeOH |
| Puromycin (20 μM) | Protein translation inhibitor | PBS/G | Water | PBS/G |
a
Stock solutions were made of the test substance (for non-water-soluble compounds) in the solvent listed. The stock solution was then added to the base buffer, resulting in the final solvent concentration shown, where applicable. Abbreviations: MeOH, methanol; EtOH, ethanol.